Search Immortality Topics:

Page 11234..1020..»


Category Archives: Biotechnology

Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression – Nature.com

K. rhaeticus culture conditions and culturing approaches

Two culture media were used in this study to culture K. rhaeticus. HS-glucose media (2% glucose, 10gl1 yeast extract, 10gl1 peptone, 2.7gl1 Na2HPO4 and 1.3gl1 citric acid, pH 5.65.8) and coconut water media (coconut water (Vita Coco), 0.05% (vol/vol) acetic acid). Coconut water media was sterilized by filtration, except in situations where more than 1l was required. In those situations, media supplements were sterilized separately and combined with coconut water, which had been opened and decanted out with aseptic technique, in the culturing container.

When K. rhaeticus was cultured on solid media, HS-glucose media was always used and supplemented with 1.5% agar. K. rhaeticus liquid cultures fell into the following two separate approaches: shaking cultures and stationary cultures. In shaking cultures, the media in use was supplemented with 2% (vol/vol) cellulase (Sigma-Aldrich, C2730) to allow for turbid growth without clumping. In stationary culture, where the goal is pellicle formation, media would be supplemented with 1% (vol/vol) ethanol to enhance pellicle production. In both approaches, where antibiotics were required for plasmid maintenance, media was supplemented with 340gml1 chloramphenicol or 200gml1 spectinomycin.

To facilitate consistency when inoculating multiple pellicles, K. rhaeticus cells would be grown in shaking growth conditions until turbid, normalized in OD600 across samples, pelleted by centrifugation and washed in the subsequent media to remove cellulase. The washed cells were used as a preculture and added, at a ratio of 1:25, into the culturing container and left in stationary conditions at 30C to form pellicles. In the case of forming large pellicles consistently (>25cm2), a glycerol aliquot approach was used. The K. rhaeticus strain of interest would be grown, shaking at 30C in 100ml of HS-glucose media until it reached an OD600 of ~0.6 to 1. At this point, the cells would be pelleted by centrifugation, washed in HS-glucose media, before being pelleted again and resuspended in 10ml of HS-glucose media containing 25% glycerol. The resuspended cells would be separated into 1ml aliquots and stored at 80C until use. When used, an aliquot would be thawed and added to the media in the final culturing container.

DNA parts and plasmids used in this study are listed in the supplementary materials. E. coli Turbo (NEB) cells were used for plasmid construction. The tyr1 DNA sequence was ordered from Twist Bioscience, with compatible 3 and 5 overhangs for entry into the KTK via Golden Gate Cloning. Constitutive tyrosinase constructs were built using the KTK. The procedures and protocols for working with the KTK are described in ref. 26. Plasmids containing the various versions of the Opto-T7RNAP system were kindly sent to us by A. Baumschlager and M. Khammash from ETH Zrich. Due to the presence of multiple KTK-incompatible restriction sites in the T7-Opto coding sequences, Gibson cloning was used to build both the pOpto-T7RNAP*(563-F2)-target plasmid and the five pOpto-T7RNAP suicide plasmids for genomic integration. The primers for Gibson cloning are listed in the supplementary materials.

K. rhaeticus electrocompetent cells were prepared as in ref. 24. K. rhaeticus cells were transformed using electroporation and selected for HS-glucose agar plates containing either 340gml1 chloramphenicol or 500gml1 spectinomycin, depending on the plasmid selection marker in use. Note, here a higher concentration of spectinomycin is used during normal culturing. Genetic constructs that were integrated into the chromosome of K. rhaeticus were done so by homologous recombination using a pUC19 suicide plasmid, as described in ref. 26.

Melanated pellicles were produced using a two-step approach. First, a tyr1 expression strain would be inoculated into a sterile culture container. Typically, 24-well deep well plates (Axygen) were used to make small pellicles. Each well contained 5ml of growth media and was inoculated at a ratio of 1:25 with preculture. Growth media was enriched with 0.5gl1 l-tyrosine and 10M CuSO4 to promote the highest eumelanin production. Once the pellicles had reached the desired thickness, they were collected, placed in a bath of sterile dH2O and washed for 1min by gently shaking by hand. The washed pellicles are then passed into a bath of eumelanin development buffer. A large ratio of buffer to pellicle was used, that is, one pellicle in 25ml of buffer in a 50-ml falcon tube; this was to prevent the overwhelming of the buffer by remaining acid in the pellicle. The pellicle would be allowed to produce eumelanin at >30C in shaking conditions over 24h.

To produce the melanated pellicle used to make the wallet, a 200300 Eurobox container was sterilized and filled with 3l of coconut water media supplemented with 0.5gl1 l-tyrosine, 10M CuSO4 and 1% ethanol. The media was inoculated with a 1ml K. rhaeticus ctyr1 glycerol aliquot and covered in a paper towel before being placed into a stationary incubator set to 30C. After 10days of growth, the pellicle was collected, washed briefly in dH2O before being placed in a 300400mm Eurobox containing 2l of concentrated eumelanin development buffer (10 PBS). The development container was then placed into a shaking incubator set to 45C and allowed to produce eumelanin over 2days, at which point the cellulose had become completely black. The melanated cellulose was then washed again to remove excess eumelanin development buffer before being autoclaved. To make the material pliable after drying, the cellulose sheet was left in a 5% glycerol solution. This glycerol process may improve the strength of dried BC by maintaining some of the properties of wet BC, by preventing hornification55. The sample was then pressed to remove bulk water and air-dried for 24h. This process typically leads to around a 98% reduction in mass due to the removal of water.

To produce the melanated pellicle used to make the shoe, a custom-shaped vessel, containing an apparatus that held a network of tightly strung yarn, was sterilized and filled with 2l of coconut water media supplemented with 0.5gl1 l-tyrosine, 10M CuSO4, 340gml1 chloramphenicol and 1% ethanol. The media was inoculated with a ~500ml precultured K. rhaeticus ptyr1 pellicle. To accommodate the fed-batch procedure and unique vessel size necessary to incorporate the yarn apparatus, the culture was left to grow at room temperature in stationary conditions, until a thin pellicle had formed. At this point, fresh coconut water media supplemented with 0.5gl1 l-tyrosine, 10M CuSO4, 340gml1 chloramphenicol and 1% ethanol was added, to raise the pellicle to just below the level of the tensed yarn. After a longer growth period of 2weeks due to lower temperature, the media was drained and replaced with concentrated eumelanin development buffer (10 PBS). The full container was placed into a shaking incubator set to 30rpm, and developed at 30C for 1day, at which point the pellicle had become completely black. The vessel was then drained of eumelanin development buffer, replaced with 70% ethanol and left overnight to sterilize. The ethanol was replaced with a 5% glycerol solution before the melanated cellulose was removed from the apparatus and wrapped around a shoe-shaped mold (last) to air-dry at 45C for 24h. Once air-dried, the shoe upper and last were placed onto a sole and photographed.

The eumelanin production assay uses a 384-square-well microtiter plate as a reaction plate. An OT-2 liquid handling robot (Opentrons) was used to prepare these reaction plates for the assay. Development buffer was placed into a deep well plate, from which 40l was transferred to each well in the reaction plate using an eight-channel 300l OT-2 Gen2 pipette. The reaction plate was kept at 4C to slow eumelanin production during plate preparation using the OT-2 thermo-module. Cells and supernatant potentially containing tyrosinase were placed into a 96-well plate. Cells were mixed in one round of aspiration using an eight-channel 20l OT-2 Gen2 pipette before 10l of cells were transferred into each well of the 384-well plate. Once full, the reaction plate was centrifuged for 10s to draw liquid to the bottom of the wells before being sealed with a Breath-Easy sealing membrane. The reaction plate was placed into a plate reader and heated to 45C to accelerate eumelanin production and prevent potential cell growth from affecting optical density readings. To measure cell density in the reaction plate, an initial measurement at OD600 is taken, after which OD405 measurements are taken every 10min for 12h, while the plate is shaken at high speed.

K. rhaeticus ptyr1, K.rhaeticus tyr1, and wild-type K. rhaeticus starter cultures were grown in 3ml of HS-glucose media, with 2% cellulase, 0.5gl1 tyrosine, 10M CuSO4 and, if appropriate, 340gml1 chloramphenicol, in shaking conditions for 24h. The cultures were normalized for OD600 and inoculated into shaking flasks containing 25ml of the same prior media for 48h. At this point, the cells were pelleted by centrifugation and the supernatant was transferred to a separate container on ice. The supernatant was sterilized using a 0.2-m filter and the pH was adjusted to pH 7 by 1M NaOH titration. The cell pellets were resuspended in eumelanin development buffer and 10l of the resulting mixture was placed into a 384-well plate alongside pH-adjusted supernatant samples and pH-adjusted cell cultures. Once full, the reaction plate was centrifuged for 10s to draw liquid to the bottom of the wells before being sealed with a Breath-Easy sealing membrane. Assay plate was run using the same protocol as used in the Eumelanin production assay.

K. rhaeticus ptyr1 was inoculated into a 24-well deep well plate, with each well containing 5ml of HS-glucose media, with 0.5gl1 tyrosine, 10M CuSO4 and 340gml1 chloramphenicol. After incubating at 30C for 7 days, pellicles were collected. Eumelanin production was initiated by placing the collected pellicles into eumelanin development buffer. A set of pellicles were held back from eumelanin production and placed into an acetate buffer containing 0.5gl1 tyrosine and 10M CuSO4 at pH 3.6 to act as a negative control. Melanated and unmelanated pellicles were sterilized by placing them in 70% ethanol overnight. Pellicles were then washed in distilled water to remove leftover ethanol and salt. Pellicles were then dried flat using a heated press set to 120C and 1ton of pressure. This process on average leads to a 98% reduction in mass of the pellicle. To facilitate this drying and prevent the pellicles from sticking to the press, pellicles were sandwiched between three layers of filter paper. Wettability tests were conducted using a KRUSS EasyDrop with 1l of water. Each contact angle measurement was derived from the average contact angle from ten back-to-back water drop images taken within 10s of drop contact with the pellicle surface.

K. rhaeticus ptyr1 was inoculated into 15-cm square Petri dishes containing 50ml of HS-glucose media, with 0.5gl1 tyrosine, 10M CuSO4 and 340gml1 chloramphenicol. After incubating at 30C for 7 days, pellicles were collected and cut into half. One half was placed into an eumelanin development buffer to initiate eumelanin production and the other half into an acetate buffer containing 0.5gl1 tyrosine and 10M CuSO4 at pH 3.6 to prevent eumelanin production. After 24h of shaking at 30C, melanated and unmelanated pellicles were removed from their respective buffers and sterilized in a 70% ethanol solution overnight. Pellicles were then washed in distilled water to remove ethanol and salts left over from the eumelanin development processes. Pellicles were then dried flat using a heated press set to 120C and 1ton of pressure. This process on average leads to a 98% reduction in mass of the pellicle. The 35-mm-long dog-bone test specimens were cut out of the dried cellulose using a Zwick ZCP 020 manual cutting press. Pellicle specimen ends reinforced with a card using Everbuild Stick 2 superglue. Dots were marked on the surface of each specimen for the optical measurement of displacement. A silver pen was used to dot melanated cellulose to generate the necessary contrast for optical measurement of displacement. Tensile tests were conducted with a Deben Microtest Tensile Stage using a load cell of 200N and cross-head speed of 0.5mmmin1.

The unmelanated pellicle was prepared by placing it into an acidic acetate buffer at pH 3.6, which prevented eumelanin synthesis and incubated in identical conditions to the melanated pellicle in the eumelanin development buffer bath. Melanated and unmelanated pellicles were prepared for SEM through the following steps. Unsterilized pellicles were placed in a 20% ethanol solution and shaken gently for 1h before being removed and placed into a 40% ethanol solution and shaken gently. This process was repeated for 60%, 80% and 100% ethanol solutions to ensure the maximum replacement of water with ethanol from the cellulose matrix. Pellicles were then flash-frozen in liquid nitrogen and freeze-dried until completely dry. The fully dried pellicles were then fixed on aluminum studs, sputter coated with gold and imaged at 5kV with a Zeiss Auriga Gemini FEG FIB-SEM.

K. rhaeticus ptyr1 and K. rhaeticus ctyr1 were separately inoculated into 3ml of HS-glucose media containing 2% (vol/vol) cellulase and 340gml1 chloramphenicol and grown shaking at 30C until turbid. The turbid cultures were then pelleted by centrifugation, washed with 1ml PBS and split into two separate 1.5ml centrifuge tubes. The cells were then pelleted again. One pellet was resuspended with 500l eumelanin development buffer to initiate eumelanin production and the other pellet was resuspended with 500l PBS to keep the cells unmelantated. The cells were incubated over 24h at 30C by which point the tube containing the cells in eumelanin development buffer had turned black. To prepare the microscope slides, 1l of melanated and unmelanated cells were placed on separate 1% agarose pads and imaged on a Nikon Ti-EX1 invert microscope with a 40 objective lens. Cells were imaged in bright field with no phase contrast to accurately represent the shade of the cells.

K. rhaeticus WT, K. rhaeticus ptyr1 and K. rhaeticus ctyr1 were inoculated into two-well deep well plates containing 50ml of HS-glucose media, with 0.5gl1 tyrosine, 10M CuSO4 and 340gml1 chloramphenicol. After 10days of incubation at 30C, pellicles were collected and placed into eumelanin development buffer. After 24h, pellicles were sterilized through autoclaving. Pellicles were then placed in a 20C freezer for 24h to minimize compression during sectioning. The frozen pellicles were sectioned by hand using a Leica DB80LX blade and imaged using a macro lens (Leica) on an RS Pro lightbox.

K. rhaeticus ptyr1 and K. rhaeticus ctyr1 were inoculated into 12.516.5cm2 two-well glass container with 200ml of HS-glucose media with 0.5gl1 tyrosine, 10 CuSO4 and 340gml1 chloramphenicol. After incubation for 7days at 30C, pellicles were collected. Eumelanin production was initiated by placing the pellicles into eumelanin development buffer. After 24h of shaking at 30C, pellicles were removed from the buffer and sterilized in 70% ethanol solution overnight. Pellicles were then washed in distilled water to remove ethanol and leftover salts. To make the material pliable after drying, replicate pellicles were placed in 0% or 5% glycerol solution overnight. Pellicles were then dried flat using a heated press set to 120C and 1ton of pressure. To facilitate this drying and prevent the pellicles from sticking to the press, pellicles were sandwiched between three layers of filter paper. Water spotting tests were adapted from ISO 105-E07:2010 standard. Eumelanated pellicles were secured onto an RS Pro lightbox, and 50l of distilled water was spotted onto each sample in triplicate. Pellicles were imaged before, immediately after and 16h after water spotting and assessed for color change.

A custom projection rig was built to project light onto the growing pellicle (Extended Data Fig. 7b). This held an acetate transparency that contained various components that would test the quality of the patterning in the pellicle. The image transparency was designed in Adobe Illustrator and printed on an HP LaserJet 500 MFP M570. Four acetate transparencies were stacked atop each other to form the final transparency. This was then sealed between glass slides and secured to the upper laboratory loop clamp. The pellicle container was sterilized and filled with 500ml of HS-glucose media, containing 0.1% (wt/vol) arabinose, 1% (vol/vol) ethanol and 170gml1 chloramphenicol. The media was then inoculated with a 1-ml K. rhaeticus pOpto-T7RNAP*(563-F2)-mCherry glycerol aliquot, and a glass lid was placed on top of the container. This glass lid was warmed before placement to prevent condensation forming on it and distorting the projection. The LED lamp was then turned on, and the lens shuttered with a piece of black card. After 3days at ~30C, a thin pellicle had formed. The lens was uncovered and the image from the transparency focused on the pellicle. Once the pellicle had been exposed to the projected image for 3days, it was collected and scanned using a FLA-5000 fluorescence scanner (Fujifilm). Image analysis was conducted using the OpenCV Python library.

A custom rig using a commercial LED projector (ViewSonic M1) was built to project light onto the growing pellicle (Extended Data Fig. 7e). The rig was draped with blackout fabric to remove outside light. A time-lapse image was designed in Adobe Illustrator to test how long a given pellicle would need to be exposed to light before an identifiable change in pigmentation could be observed. In this image, blue is represented by an RGB value of (0, 0, 255), cyan by (0, 255, 255), white by (255, 255, 255) and black by (0, 0, 0) (Fig. 4h). The pellicle container was sterilized and filled with 1l of coconut water media, containing 1% (wt/vol) arabinose, 0.5gl1 l-tyrosine, 10M CuSO4, 1% (vol/vol) ethanol and 200gml1 spectinomycin. The media was then inoculated with a 1-ml K. rhaeticus Opto-T7RNAP(563-F1)-tyr1 glycerol aliquot and the culture container was covered with foil. While this version of the optogenetic rig did contain a heater, in practice, we found this was only effective at heating the growth area by 12C above room temperature. After 8days at near room temperature (~20C), a thin pellicle had formed. The foil was then removed, the projector focused on the surface of the pellicle and the 80-h video started. After 80h, the pellicle was collected and placed into a 300400mm Eurobox containing 2l of concentrated eumelanin development buffer and left to develop in stationary conditions at 30C until a discernible pattern could be identified. The pellicle was then washed in dH2O to remove eumelanin that had not accumulated within the pellicle. Densitometry scans of the pellicle were taken using an Amersham Typhoon scanner (GE) and set to the digi-blue digitalization setting.

K. rhaeticus Opto-T7RNAP strains carrying the pT7-mCherry plasmid and K. rhaeticus pOpto-T7RNAP*(563-F2)-mCherry were cultured, in darkness, shaking in 3ml of HS-glucose media with 2% cellulase, containing either spectinomycin at 200gml1 or chloramphenicol at 340gml1 depending on the plasmid. When all cultures had become turbid, the OD600 was measured and cultures were all either diluted or concentrated to an OD600 of 1, before being inoculated (a ratio of 1:10) into a 96-well deep well plate containing 270l HS-glucose media with 2% cellulase and either 0, 1, 10 or 100mgml1 of arabinose. Where appropriate, spectinomycin at 200gml1 and chloramphenicol at 340gml1 were added to the wells. After 18h of shaking growth at 30C in darkness, cells were split across two clear 96-well plates, diluted 1:2 into fresh media with a matching arabinose concentration. One plate was placed onto a shaker under a blue LED flood light and the other plate was wrapped in foil and placed on the same shaker. Both plates were sealed with a Breath-Easy sealing membrane. After 6h in the two lighting conditions at 30C and fast shaking, the cells were placed into a plate reader, and red fluorescence in each well was measured using ex of 590nm and em of 645nm as well as cell density at OD600.

The Opto-T7RNAP K. rhaeticus strains carrying the pT7-tyr1 plasmid and K. rhaeticus pOpto-T7RNAP(563-F1)-tyr were cultured in the same manner as the mCherry strainswith the exception that the HS-glucose was supplemented with 0.5gl1 tyrosine and 10M CuSO4. The approach to exposing the cells to blue light was also the same as the mCherry strains, except, after 6h of exposure time, the two plates were entered into the eumelanin production assay procedure. The two plates were placed onto the OT-2 deck and samples from both plates were mixed with eumelanin development buffer in a 384-well reaction plate. Each well in the two 96-well plates was sampled twice in the 384 reaction plate to give two technical replicates for each well. These two replicates were then averaged during analysis.

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Read the original here:
Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression - Nature.com

Posted in Biotechnology | Comments Off on Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression – Nature.com

Biotechnology Market Size to Reach USD 5.68 Trillion by 2033 – BioSpace

According to the latest research by Nova One Advisor, the global biotechnology market size was valued at USD 1.54 Trillion in 2023 and is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% from 2024 to 2033

Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)@ https://www.novaoneadvisor.com/report/sample/6732

The market is driven by strong government support through initiatives aimed at the modernization of regulatory framework, improvements in approval processes & reimbursement policies, as well as standardization of clinical studies. The growing foothold ofpersonalized medicineand an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting the market revenue.

The COVID-19 pandemic has positively impacted the biotechnology market by propelling a rise in opportunities and advancements for drug development and manufacturing of vaccines for the disease. For instance, in 2021, over 11 billion doses of COVID-19 vaccine were produced globally, resulting in vaccination of about half of the worlds population within a year. Furthermore, the success of mRNA vaccines and accelerated approval processes have led to a surge in vaccine-related revenues, as evident by a combined revenue generation of around USD 31.9 billion in 2021 from Moderna, Pfizer/BioNTech, and Johnson & Johnson vaccines.

Expanding demand for biotechnology tools for agricultural applications including micro-propagation, molecular breeding, tissue culturing, conventional plant breeding & development of genetically modified crops, among others, have boosted the market growth. Moreover, genetically modified crops and herbicide-tolerant & insect resistant seeds are witnessing an increasing popularity and are contributing to the market growth. Rise in adoption of tissue culture technology for production of novel rice variants and disease- & pest-free banana varieties in regions of South Asia and Africa, and use of the technology for cloning of disease-free and nutritious plant varieties have propelled the agricultural applications for biotechnology.

The market is also driven by the presence of strong clinical trial pipeline and funding opportunities available in tissue engineering and regeneration technologies. As per the Alliance for Regenerative Medicine, companies developing cell and gene therapies raised over USD 23.1 billion investments globally in 2021, an increase of about 16% over 2020s total of USD 19.9 billion. Clinical success of leading gene therapy players in 2021, such as promising results from an in vivo CRISPR treatment for transthyretin amyloidosis, developed by Intellia Therapeutics and Regeneron, are significantly affecting the market growth.

Rising demand for clinical solutions for the treatment of chronic diseases such as cancer, diabetes, age-related macular degeneration, and almost all forms of arthritis are anticipated to boost the market. Major firms are investigating and developing pipeline products for diabetes and neurological disorders, such as Parkinsons & Alzheimers diseases, various types of cancers and cardiovascular diseases. For instance, according to clinicaltrials.gov, as of January 2021, there were 126 agents in clinical trials for the treatment of Alzheimer's disease, with 28 treatments in phase III trials.

Life sciences and healthcare sectors are experiencing a widespread use of fermentation technology and have positively impacted the market growth. Several modifications and advancements in the conventional bioreactors, such as introduction of simplified bioreactors and vortex bioreactors have led to improvements in the fermentation technology and growth in its adoption. Furthermore, vortex bioreactors have also been improvised for wastewater processing, to offer an enhanced operational feasibility. These modifications and improvement in fermentation technology are expected to accelerate market growth in the near future.

CAR T andTCR T-cell therapiesare being explored as potential treatment options against chronic viral infections, such as HIV, hepatitis B, and SARS-CoV-2. For instance, scientists at Duke-NUS Medical School are evaluating the use of T-cell therapy in combating the COVID-19 infection. The scientists have demonstrated that TCR-redirected T cells exhibit a functional profile comparable to that of SARS-specific CD8 memory T cells obtained from patients who have recovered from the infection. Such investigations are anticipated to spur further research prospects in this domain and drive the market growth.

Biotechnological techniques includingstem celltechnology, DNA fingerprinting, and genetic engineering, among other, are gaining significant traction since past few years. Technological advancement in stem cell therapeutics, increasing demand forbiologics, and a growing focus on the development of personalized medicines have resulted in a growing market for stem cell technologies. DNA fingerprinting applications are on the rise in forensic science, and for investigation of family relationships in animal populations as well as measurement of the extent of inbreeding. Similarly, genetic engineering and cloning techniques are being increasingly used in animal breeding and for manufacturing of complex biological substances.

Key Takeaways:

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/6732

TYPES OF BIOTECHNOLOGY

Like the stripes of the rainbow, the different biotechnology applications are grouped generally into seven colours orresearch and development areas.In this section, we highlight the most relevant of each of them.

To these typologies, four further sub-categories with corresponding colours have more recently been added:

Biotechnology Market Trends

Ask here for customization study@ https://www.novaoneadvisor.com/report/customization/6732

Biotechnology Market Size in the U.S. 2024 to 2033

The U.S. biotechnology market size was valued at USD 246.18 billion in 2023 and is anticipated to reach around USD 763.82 billion by 2033, poised to grow at a CAGR of 11.90% from 2024 to 2033.

North America accounted for the largest share of 41% in 2023. The regional market is witnessing growth due to several factors, such as the presence of key players, extensive R&D activities, and high healthcare expenditure. The region has a high penetration of genomics, proteomics, and cell biology-based platforms that is accelerating the adoption oflife sciences tools. Furthermore, rise in prevalence of chronic diseases and rising adoption of personalized medicine applications for the treatment of life-threatening disorders is expected to positively impact the market growth in the region.

Asia Pacific is expected to expand at the fastest growth rate from 2024 to 2033. The growth of the regional market can be attributed to increasing investments and improvement in healthcare infrastructure, favorable government initiatives, and expansion strategies from key market players. For instance, in February 2022, Moderna Inc. announced its plans for a geographic expansion of its commercial network in Asia through opening of four new subsidiaries in Malaysia, Singapore, Hong Kong, and Taiwan. In addition, biopharmaceutical collaborations, such as Kiniksa Pharmaceuticals and Huadong Medicines strategic collaboration for development and commercialization of Kiniksas ARCALYST and mavrilimumab in the Asia-Pacific region are expected to drive the market growth.

Segments Insights:

Technology Insights

DNA sequencingheld a significant market share of 17.53% in 2023 which can be attributed to declining sequencing costs and rising penetration of advanced DNA sequencing techniques. Government funding in genetic research has enabled a rise in applications of sequencing for better understanding of diseases. For instance, in May 2021, a USD 10.7 million NIH grant was awarded to the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine in St. Louis, for investigation of the genetic basis of Alzheimers disease.

Nanobiotechnology is expected to grow at a significant growth rate from 2024 to 2033 owing to an increase innanomedicineapprovals and the advent of advanced technology. For instance, applications of theranostics nanoparticles have gained impetus for enabling prompt diagnosis and customization of treatment options for multiple disorders at once. Factors such as low toxicity, smaller size, and chemical plasticity of nanoparticles have proved to be beneficial for overcoming the limitation associated with conventional routes of generic drug administration. Furthermore, tissue engineering and regeneration medicine held a significant share due to government and private investments in the field, along with high healthcare spending and presence of significant number of mature and emerging players in this space. These factors are expected to drive the segment growth over the forecast period.

Application Insights

The health application segment accounted for the largest share in 2023. Growing disease burden, increasing availability of agri-biotech & bio-services, and technological developments in bio-industrial sector are expected to drive the segment growth. In addition, the segment growth is also fueled by significant advancements in the fields ofArtificial Intelligence(AI),machine learning, andbig data, which are expected to increase penetration of bioinformatics applications, especially in industries such as food and beverages.

Moreover, collaborative efforts and partnerships aimed at development and commercialization of new therapeutic platforms and molecules are anticipated to drive the market growth. For instance, in January 2021, Novartis collaborated with Alnylam for exploring the application of the latters siRNA technology for development of targeted therapy for restoration of liver function. Similarly, in September 2021, AstraZeneca and VaxEquity collaborated for development and commercialization of self-amplifyingRNA therapeuticsplatform to explore novel therapeutic programs. Furthermore, growing demand for biosimilars and rising applications of precision medicine are expected to boost segment growth during the forecast period.

Regional Insights

North America accounted for the largest share of 41% in 2023. The regional market is witnessing growth due to several factors, such as the presence of key players, extensive R&D activities, and high healthcare expenditure. The region has a high penetration of genomics, proteomics, and cell biology-based platforms that is accelerating the adoption oflife sciences tools. Furthermore, rise in prevalence of chronic diseases and rising adoption of personalized medicine applications for the treatment of life threatening disorders is expected to positively impact the market growth in the region.

Asia Pacific is expected to expand at the fastest growth rate from 2024 to 2033. The growth of the regional market can be attributed to increasing investments and improvement in healthcare infrastructure, favorable government initiatives, and expansion strategies from key market players. For instance, in February 2022, Moderna Inc. announced its plans for a geographic expansion of its commercial network in Asia through opening of four new subsidiaries in Malaysia, Singapore, Hong Kong, and Taiwan. In addition, biopharmaceutical collaborations, such as Kiniksa Pharmaceuticals and Huadong Medicines strategic collaboration for development and commercialization of Kiniksas ARCALYST and mavrilimumab in the Asia-Pacific region are expected to drive the market growth.

Recent Developments

Some of the prominent players in the Biotechnology Market include:

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Biotechnology market.

By Technology

By Application

By Region

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/6732

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com|

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |

Europe: +44 2080772818

See the article here:
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033 - BioSpace

Posted in Biotechnology | Comments Off on Biotechnology Market Size to Reach USD 5.68 Trillion by 2033 – BioSpace

Biotechnology Permits | Animal and Plant Health Inspection Service – USDA APHIS

APHIS regulates the importation, interstate movement, or environmental release (i.e., outdoor field trials) of certain organisms developed using genetic engineering (including plants, insects, and microbes) that may pose a plant pest risk. Permit applications, which are carefully reviewed by APHIS regulatory scientists, provide details about the nature of the organism and the conditions that will be used to prevent the spread and establishment of the organism in the environment. A permit may include additional conditions to help prevent unauthorized release into the environment.

Link:
Biotechnology Permits | Animal and Plant Health Inspection Service - USDA APHIS

Posted in Biotechnology | Comments Off on Biotechnology Permits | Animal and Plant Health Inspection Service – USDA APHIS

Plastic-free vegan leather that dyes itself grown from bacteria – EurekAlert

image:

The bacteria grown and dyed wallet

Credit: Tom Ellis/Marcus Walker/Imperial College London

Researchers at Imperial College London have genetically engineered bacteria to grow animal- and plastic-free leather that dyes itself.

In recent years, scientists and companies have started using microbes to grow sustainable textiles or to make dyes for industry but this is the first time bacteria have been engineered to produce a material and its own pigment simultaneously.

Synthetic chemical dyeing is one of the most environmentally toxic processes in fashion, and black dyes especially those used in colouring leather are particularly harmful. The researchers at Imperial set out to use biology to solve this.

In tackling the problem, the researchers say their self-dyeing vegan, plastic-free leather, which has been fashioned into shoe and wallet prototypes, represents a step forward in the quest for more sustainable fashion.

Their new process, which has been published in the journal Nature Biotechnology, could also theoretically be adapted to have bacteria grow materials with various vibrant colours and patterns, and to make more sustainable alternatives to other textiles such as cotton and cashmere.

Lead author Professor Tom Ellis, from Imperial College Londons Department of Bioengineering, said: Inventing a new, faster way to produce sustainable, self-dyed leather alternatives is a major achievement for synthetic biology and sustainable fashion.

Bacterial cellulose is inherently vegan, and its growth requires a tiny fraction of the carbon emissions, water, land use and time of farming cows for leather.

"Unlike plastic-based leather alternatives, bacterial cellulose can also be made without petrochemicals, and will biodegrade safely and non-toxically in the environment.

Designer collaboration

The researchers created the self-dyeing leather alternative by modifying the genes of a bacteria species that produces sheets of microbial cellulose a strong, flexible and malleable material that is already commonly used in food, cosmetics and textiles. The genetic modifications 'instructed the same microbes that were growing the material to also produce the dark black pigment, eumelanin.

They worked with designers to grow the upper part of a shoe (without the sole) by growing a sheet of bacterial cellulose in a bespoke, shoe-shaped vessel. After 14 days of growth wherein the cellulose took on the correct shape, they subjected the shoe to two days of gentle shaking at 30C to activate the production of black pigment from the bacteria so that it dyed the material from the inside.

They also made a black wallet by growing two separate cellulose sheets, cutting them to size, and sewing them together.

As well as the prototypes, the researchers demonstrated that the bacteria can be engineered using genes from other microbes to produce colours in response to blue light. By projecting a pattern, or logo, onto the sheets using blue light, the bacteria respond by producing coloured proteins which then glow.

This allows them to project patterns and logos onto the bacterial cultures as the material grows, resulting in patterns and logos forming from within the material.

Co-author Dr Kenneth Walker, who conducted the work at Imperial College Londons Department of Bioengineering and now works in industry, said: Our technique works at large enough scales to create real-life products, as shown by our prototypes. From here, we can consider aesthetics as well as alternative shapes, patterns, textiles, and colours.

"The work also shows the impact that can happen when scientists and designers work together. As current and future users of new bacteria-grown textiles, designers have a key role in championing exciting new materials and giving expert feedback to improve form, function, and the switch to sustainable fashion.

Greener clothes

The research team are now experimenting with a variety of coloured pigments to use those that can also be produced by the material-growing microbes.

The researchers and collaborators have also just won 2 million in funding from Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), to use engineering biology and bacterial cellulose to solve more of fashions problems, such as the use of toxic chromium in leathers production lines.

Professor Ellis said: Microbes are already directly addressing many of the problems of animal and plastic-based leather, and we plan to get them ready to expand into new colours, materials and maybe patterns too.

We look forward to working with the fashion industry to make the clothes we wear greener throughout the whole production line.

The authors worked closely with Modern Synthesis, a London-based biodesign and materials company, who specialise in innovative microbial cellulose products.

This work was funded by Engineering and Physical Sciences Research Council and BBSRC, both part of UKRI.

Nature Biotechnology

Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression

2-Apr-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

More:
Plastic-free vegan leather that dyes itself grown from bacteria - EurekAlert

Posted in Biotechnology | Comments Off on Plastic-free vegan leather that dyes itself grown from bacteria – EurekAlert

Genetically encoding colors and images into bioengineered microbial materials – Nature.com

Publishers note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Walker, K. T. et al. Self-pigmenting textiles grown from cellulose-producing bacteria with engineered tyrosinase expression. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02194-3 (2024).

See more here:
Genetically encoding colors and images into bioengineered microbial materials - Nature.com

Posted in Biotechnology | Comments Off on Genetically encoding colors and images into bioengineered microbial materials – Nature.com

Head of ClinicalTrials.gov job with National Library of Medicine, National Center for Biotechnology Information … – The Chronicle of Higher…

The National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM), National Institutes of Health (NIH) performs research on computational biology and creates and maintains information systems and computational tools for the biological research community. The NCBI is seeking a Program Head to manage the ClinicalTrials.gov project, a critical, highly visible, informational NIH resource, by providing leadership and technical and scientific direction in support of the transparency and disclosure of clinical research studies and their results. ClinicalTrials.gov contains information about ongoing and completed clinical studies from sponsors in the U.S. and abroad. It consists of a study registry and results database. The registry allows prospective participants to find information about recruiting studies of interest, enables researchers to characterize the clinical research landscape, provides an official repository for publicly declaring study protocol details, and facilitates the tracking of study completion and results disclosure. The results database, which complements journal publication, allows researchers to find complete, structured summary results based on the prespecified protocol for studies in an area of interest, thereby mitigating publication bias and selective reporting. This position directs program activities to optimize the value of the resource to stakeholders, while ensuring it meets policy and legal requirements. As of December 2023, ClinicalTrials.gov has over 473,000 study records, and over 61,000 records with results. More than 100,000 visitors use the website daily to find and learn about clinical studies. The data submission system, PRS (Protocol Registration and Results database), has about 20,000 unique logins per month and over 250,000 users. The Program Head manages over 40 scientific, technical, and administrative staff, is active in conducting and publishing research, participates in numerous scientific and policy activities and collaborations, and serves in an external advisory capacity.

Position Requirements

Candidates may be U.S. citizen, must have either a Ph.D., M.D. or equivalent doctoral degree, and must have experience in clinical trials methodologies, drug development procedures and clinical trials registries. The successful candidate will have demonstrated the skill and ability to direct, organize, and coordinate complex research and development projects and will have exceptional technical competence. Candidates should also have excellent communication skills and a proven ability to successfully engage with others to create useful resources and to achieve shared objectives. Salary and benefits are competitive, commensurate with education and experience.

How to Apply

Visit http://www.USAJobs.gov and access the detailed vacancy announcement https://www.usajobs.gov/job/778732800 beginning April 27th, 2024.Applications must be submitted online by 11:59 p.m. on May 1st, 2024.

Email ncbijobs@ncbi.nlm.nih.gov with questions or for more information about the position. Email Doug Bruno (douglas.bruno@nih.gov) with questions regarding how to apply. Visit NLM Careers to learn more about NLM and how you can play a role in this exciting and dynamic research organization.

HHS, NIH, and NLM are equal opportunity employers. DHHSandNIHareEqualOpportunityEmployers

Originally posted here:
Head of ClinicalTrials.gov job with National Library of Medicine, National Center for Biotechnology Information ... - The Chronicle of Higher...

Posted in Biotechnology | Comments Off on Head of ClinicalTrials.gov job with National Library of Medicine, National Center for Biotechnology Information … – The Chronicle of Higher…